Outcomes | Anticipated absolute effects*(95% CI) | Relative effect(95% CI) | № of participants (studies) | Certainty of the evidence(GRADE) | Comments | |
---|---|---|---|---|---|---|
Risk with placebo | Risk with galcanezumab | |||||
Reduction in migraine days follow up: 6 months | The mean reduction in migraine days was −2.6 days | The mean reduction in migraine days in the intervention group was 2.0 days fewer (2.4 fewer to 1.5 fewer) | – | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 120 mg results in reduction in migraine days compared with placebo. |
Reduction in use of acute attack medication follow up: 6 months | The mean reduction in use of acute attack medication was −2.1 days | The mean reduction in use of acute attack medication in the intervention group was 1.8 days fewer (2.1 fewer to 1.5 fewer) | – | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 120 mg results in reduction in use of acute attack medication compared with placebo. |
Improvement in functional MSQ RFR scorefollow up: 6 months | The mean improvement in functional MSQ RFR score was 22.2 points | The mean improvement in functional MSQ RFR score in the intervention group was 8.3 points higher (6.6 higher to 10.0 higher) | – | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 120 mg results in improvement in functional MSQ RFR score compared with placebo. |
At least 50% reduction in days of migraine follow up: 6 months | 372 per 1000 | 608 per 1000 (543 to 681) | RR 1.6326(1.4578 to 1.8283) | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 120 mg results in at least 50% reduction of days of migraine compared with placebo. |
Serious adverse events follow up: 12–6 months | 25 per 1000 | 58 per 1000 (25 to 135) | RR 2.2738(0.9732 to 5.3128) | 1330(2 RCT) | ⨁⨁⨁⨁HIGH | Treatment with galcanezumab 120 mg results a small possibly unimportant effect in serious adverse events occurrence compared with placebo |
Mortality follow up: 3–6 months | 0 per 1000 | 0 per 1000(0 to 0) | not estimable | 1330(2 RCT) | No deaths occurred during the double-blind treatment phase of the trial. |